ReviewThe Psychiatric clinics of North America2014
Pharmacological treatment of obsessive-compulsive disorder.
Review in The Psychiatric clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Optimizing non-invasive brain stimulation for obsessive-compulsive disorder: a systematic review of protocol heterogeneity, personalized targets, and adjunctive efficacy.BMC psychiatry · 2026Pooled it
- Does early non-improvement predict treatment failure in pharmacotherapy for obsessive-compulsive disorder? A diagnostic test accuracy meta-analysis with individual participant data.Psychological medicine · 2025Pooled it
- CREB: A Promising Therapeutic Target for Treating Psychiatric Disorders.Current neuropharmacology · 2024Pooled it
- The safety and efficacy of N-acetylcysteine as an augmentation in the treatment of obsessive-compulsive disorder in adults: a systematic review and meta-analysis of randomized clinical trials.Frontiers in psychiatry · 2024Pooled it
- Economic Analyses of Obsessive-Compulsive Disorder Interventions: A Systematic Review.PharmacoEconomics · 2023Pooled it
- Motor cortical inhibitory deficits in patients with obsessive-compulsive disorder-A systematic review and meta-analysis of transcranial magnetic stimulation literature.Frontiers in psychiatry · 2022Pooled it
- The effect of acupoint stimulation as an adjuvant therapy for obsessive-compulsive disorder: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Tolerability and adequate therapeutic dosage of oral clomipramine for the treatment of premature ejaculation: A randomized, double-blind, placebo-controlled, fixed-dose, parallel-grouped clinical study.International journal of impotence research · 2018Trial
- Decoding functional cough in pediatrics: differentiating tic, psychogenic, and compulsive phenotypes for targeted intervention.European journal of pediatrics · 2026Review
- Cellular and molecular coding of habit-driven behavior in the dorsal raphe nucleus.bioRxiv : the preprint server for biology · 2026Article
- Case Report: A Multimodal Treatment Approach Combining Multi-Target rTMS with a Modified, Largely Self-Administered, Clinician-Supervised Exposure and Response Prevention Protocol Using a Verbal Termination Cue in Two Patients with Severe Obsessive-Compulsive Disorder.Journal of clinical medicine · 2026Article
- Article
- Article
- Directional genetic relationships between obsessive-compulsive disorder and bipolar disorder and schizophrenia.medRxiv : the preprint server for health sciences · 2026Article
- Increased Serum GLO-1 Levels Are Associated With the Pathophysiology and Development of Obsessive-Compulsive Disorder: Findings From a Case-Control Study.Health science reports · 2026Article
- Review
- Treatment of therapy-resistant OCD with application of transcranial alternating current stimulation (tACS): a case series.BMC psychiatry · 2026Article
- Circuit-based neuromodulation for obsessive-compulsive disorder: a review of prior and emerging methods.Frontiers in psychiatry · 2026Review
- Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study.International clinical psychopharmacology · 2025Observational
- Peripheral Blood Biomarkers Reveal Dysregulated Monoaminergic Pathways in Obsessive-Compulsive Disorder: A Transcriptional and Epigenetic Analysis.International journal of molecular sciences · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Obsessive-compulsive disorder (OCD) affects up to 2.5% of the population of the course of a lifetime and produces substantial morbidity. Approximately 70% of patients can experience significant symptomatic relief with appropriate pharmacotherapy. Selective serotonin reuptake inhibitors are the mainstay of pharmacological treatment. These drugs are typically used at higher doses and for longer periods than in depression. Proven second-line treatments include the tricyclic clomipramine and the addition of low-dose neuroleptic medications. OCD refractory to available treatments remains a profound clinical challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.